Skip to content

Clinical serum markers in patients with nontraumatic osteonecrosis of the femoral head and osteoarthritis and related studies

Clinical serum markers in patients with nontraumatic osteonecrosis of the femoral head and osteoarthritis and related studies

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061238
Enrollment
Unknown
Registered
2022-06-17
Start date
2022-07-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, femoral head necrosis

Interventions

NONFH conforms to the Guidelines for the Clinical Diagnosis and treatment of Adult femoral head necrosis in China (2020).
Index test:Apolipoprotein&#32
A-IV,&#32
apolipoprotein&#32
serum&#32
leucocyte&#32
(LECT2),&#32
I&#32
converting&#32
enzyme&#32
(ACE),&#32
inducer&#32

Sponsors

Linyi People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with osteoarthritis are included as follows: (1) Patients diagnosed with knee osteoarthritis; (2) The patient is over 18 years old, and liver and kidney diseases, malignant tumors and other systemic diseases are excluded; (3) Exclude joint diseases such as rheumatism and rheumatoid; (4) No history of joint drug injection, painkiller drug use, or glucocorticoid drug use within 3 months before blood drawing; 2. Patients with non-traumatic femoral head necrosis include the following persons: (1) NONFH complies with the Guidelines for Clinical Diagnosis and Treatment of Adult Necrosis of the Femoral Head in China (2020); (2) Association Research Circulation Osseous (ARCO) Phase I-IV; (3) Age > 18 years old; (4) Alcoholic ONFH, with a weekly ethanol intake > 400 ml for more than 6 months and diagnosed within 1 year; (5) Hormonal ONFH, taking prednisolone > 2 g or medication cycle for more than 3 months, and diagnosed within 2 years; (6) Idiopathic ONFH without other obvious predisposing factors; (7) Single factor causes disease.

Exclusion criteria

Exclusion criteria: 1. Those who have suffered from serious basic diseases in the past that affect the accuracy of experimental data and cognitive dysfunction; 2. Suffering from metabolic bone disease or taking drugs that affect bone metabolism recently; 3. Repeated inclusion of case data or incomplete information; 4. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Apoprotein D;Apolipoprotein A-IV, ApoA-?;Human cryptothermal protein, NLRP3;White blood cell derivation, LECT2;Angiotensin converting enzyme, ACE;Hypoxia-inducible factor-1, HIF-1a;

Countries

China

Contacts

Public ContactBiaofang Wei

Linyi People's Hospital

542300117@qq.com+86 15612293570

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026